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Abstract  
Elevation of the DNA unwinding helicase RECQL4 which participates in various 
DNA repair pathways has been suggested to contribute to the pathogenicity of 
various human cancers, including gastric cancer. In this study, we addressed the 
prognostic and chemotherapeutic significance of RECQL4 in human gastric cancer 
(GC) which has yet to be determined. We observed significant increases in RECQL4 
mRNA or protein in >70% of three independent sets of human GC specimens 
examined, relative to normal gastric tissues. Strikingly, high RECQL4 expression in 
primary tumors correlated well with poor survival and GC lines with high RECQL4 
expression displayed increased resistance to cisplatin treatment. Mechanistic 
investigations revealed a novel role for RECQL4 in transcriptional regulation of the 
multidrug resistance gene MDR1, through a physical interaction with the 
transcription factor YB1. Notably, ectopic expression of RECQL4 in 
cisplatin-sensitive GC cells with low endogenous RECQL4 was sufficient to render 
them resistant to cisplatin, in a manner associated with YB1 elevation and MDR1 
activation. Conversely, RECQL4 silencing in cisplatin-resistant GC cells with high 
endogenous RECQL4 suppressed YB1 phosphorylation, reduced MDR1 expression 
and re-sensitizes cells to cisplatin. In establishing RECQL4 as a critical mediator of 
cisplatin resistance in GC cells, our findings provide a therapeutic rationale to target 
RECQL4 or the downstream AKT-YB1-MDR1 axis to improve GC treatment.  
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Introduction 
Systemic chemotherapy is the main treatment option for gastric cancer (GC) 
patients as GC is often diagnosed at an advanced stage and surgical removal is not 
feasible. However, prognosis and clinical response are highly variable even for the 
same grade and stage of the tumors and chemo resistance chiefly contributes to 
treatment failure and recurrence in GC patients (1). Therefore, understanding the 
molecular/mechanistic basis for the chemo resistance in GC is essential not only for 
devising a better treatment modality but also for developing new chemo sensitization 
strategies to improve GC patient survival in the future. 
Cisplatin (cis-diamminedichloroplatinum) is one of the most frequently used 
chemotherapeutic drugs in clinical GC treatment settings. The most prominent mode 
of its action is to initiate an intrinsic apoptotic pathway through DNA damage 
response activation (2). Many GC patients display cisplatin resistance through 
multiple mechanism(s) including a decreased uptake and/or an increased efﬂux of 
cisplatin mediated by speciﬁc transporters, such as MDRs and ATP7B (3-5). Also, 
constitutive activation of DNA damage response (DDR) pathways owing to elevated 
expression of DNA repair genes also contributes to chemo resistance by efficient 
reversal of cisplatin-DNA adducts (6). 
RECQL4, a member of RECQ helicase family with DNA-unwinding activity (7), 
plays an important role in maintaining the stability of nuclear (8) and mitochondrial 
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genomes (9-11). This is well supported by the existence of three human autosomal 
recessive disorders Rothmund-Thomson syndrome (RTS) (12), RAPADILLINO (13) 
and Baller-Gerold syndrome (BGS), all of them owing to mutations in RECQL4 (14). 
Mutational loss of RECQL4 is associated with increased risk for osteosarcoma 
development in RTS patients (15). Additionally, primary fibroblasts from RTS 
patients have an increased sensitivity to genotoxic agents (16). RECQL4 had recently 
been found to be significantly associated with clinical outcome and RECQL4 
suppression sensitized the breast cancer cells to DNA damaging agents (17, 18).  
Although aberrant expression of RECQL4 has been reported in sporadic 
osteoblastoma (19), breast and prostate cancer cells and tissues (20, 21), its 
prognostic and chemotherapeutic significance in GC are not known. In this study, we 
demonstrated RECQL4 expression is aberrantly elevated frequently in both clinical 
GC samples and tumor cell lines, and a higher RECQL4 expression renders the GC 
cells more resistance to cisplatin treatment. We further established a molecular link 
between RECQL4 expression and cisplatin resistance, in which RECQL4 potentiates 
YB1 phosphorylation through enhancing AKT and YB1 interaction, suggesting that 
RECQL4 is a critical determinant of cisplatin resistance in GC cells through 
regulation of AKT-YB1-MDR1 pathway. 
 
Materials and Methods 
Cell lines and antibodies 
 The human embryonic kidney HEK293 cell line was ordered in 2012, gastric 
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cancer cell lines AGS and NCI-N87 were ordered in 2013, and SNU-1 and SNU-16 
were ordered in 2015 from ATCC. MKN45 and HGC-27 were ordered in 2013 from 
the Japanese Collection of Research Bioresources and the European Collection of 
Cell Culture, UK, respectively. MGC-803 was ordered in 2013 from Cell Resource 
Center, Chinese Academy of Medical Sciences, and authenticated using Short 
Tandem Repeat (STR) profiling analysis by this Center on Dec. 30, 2015. MKN45, 
SNU-1 and SNU-16 cell lines were STR-authenticated on Nov. 24, 2015 by Cobioer 
Biosciences Co. LTD, Nanjing, China. AGS, NCI-N87, HGC-27 and HEK293 were 
STR-authenticated on Dec. 8, 2015 by Shanghai Biowing Applied Biotechnology Co. 
LTD, Shanghai, China.   
Antibodies: RECQL4 from Novus Biologicals (#25470002) and Cell signaling 
(#2814); AKT (#9272), p-AKT (#9271), YB1 (#4202) and p-YB1 (#2900) from Cell 
Signaling; MVP (ab175239) and MDR1 (ab129450) from Abcam; GAPDH 
(MAB374) from Millipore and β-actin (A1978) from Sigma.     
 
GC tissue array and clinical samples 
 TissueScan Human gastroesophogeal cancer tissue qPCR array was ordered from 
Origene (#HGRT101, Rockville, MD 20850). Eleven pairs of human gastric 
adenocarcinomas and matched normal gastric specimens were collected from the 
Department of Medical Oncology, Bethune International Peace Hospital, 
Shijiazhuang, China. The study on human GC samples has been approved by the 
Ethics Committee of Beijing Institute of Genomics.  
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Immunohistochemistry (IHC) on GC patient samples 
 Patient demographics about 142 gastric adenocarcinoma cases treated at 
Nottingham University Hospitals (NUH) between 2001 and 2006 were summarized 
in Supplementary Table S1. This cohort, comprised of well-characterized patient 
samples, was used for a wide range of biomarker studies (22-24). Approval from the 
Ethics Committee of Nottingham University Hospital, UK was obtained for this 
study.  
RECQL4 expression was carried out on TMA slides with the primary 
anti-RECQL4 antibody (#25470002, Novus Biologicals) at a dilution of 1:175. 
Whole field inspection of the core was scored and intensities of nuclear or 
cytoplasmic staining were grouped as follows: 0 = no staining, 1 = weak staining, 2 = 
moderate staining, 3 = strong staining. The percentage of each category was 
estimated (0-100%). H-score (range 0-300) was calculated by multiplying intensity 
of staining and percentage staining. Low/negative RECQL4 cytoplasmic expression 
was defined by mean of H-score of <122. Low/negative RECQL4 nuclear expression 
was defined by mean of H-score of <179.  
 
Statistical analysis 
Statistical analysis of data was performed using SPSS version 20.0 for Windows 
(SPSS Inc, Chicago, IL, USA). Survival rates were calculated from the time of 
diagnosis until the end of the follow up period and Kaplan Meier curves were plotted. 
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The statistical significance of differences between survival rates was determined 
using the log-rank test. P values ≤ 0.05 was considered as statistically significant.  
 
MTT assay and cisplatin treatment 
Cell survival was measured by the 3-(4,5-dimethylthiazol-2-yl)-2,5- 
diphenyltetrazolium bromide (MTT) assay. Cells were seeded at a density of 5,000 
cells per well in 96-well plates and incubated at 37℃ in humidified 5% CO2 for 12 h. 
Cells were then exposed to different concentrations of cisplatin for 72 h, and cellular 
viability was quantified by the MTT assay following the manufacturer's instructions 
(Molecular Probes). Absorbance values at 540 nm were read on a Spectra Max 250 
spectrophotometer (Molecular Devices). All MTT assays include 10 duplicated wells 
for each time-point of each cell line. The data represent mean ± SD from three 
independent experiments.  
 
Dual-Luciferase assay 
A 256 bp length of MDR1 gene promoter region (‒188-+68) containing Y-box 
consensus sequence used for luciferase reporter assay was ampliﬁed by PCR using 
the following primer pair: forward: 5’-ggggtaccGCAACGGAAGCCAGAACATT-3’, 
reverse: 5’-cccaagcttTGGAAAGACCTAAAGGAAACGA-3’. The PCR fragment 
was then cloned into the KpnI/HindIII sites of pGL3-Basic vector, and verified by 
sequencing. The pGL3-MDR1pro plasmid was transiently transfected into 
YB1-silenced MGC803/Tet-on/Flag-RECQL4 cells with YB1 reconstitution or/and 
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Dox-induced expression of RECQL4. Luciferase activity was measured following 
the dual-luciferase assay protocol (Promega).  
 
Adenovirus vector-mediated knock down of RECQL4 and YB1 expression 
To generate shRECQL4 and shYB1 Adenovirus constructs, a 21 mer RECQL4 
shRNA (GCTCAAGGCCAATCTGAAAGG, 366–386, Accession No. NM_004260) 
and two 21 mer YB1 shRNAs (GGTCATCGCAACGAAGGTT, 330-348; 
GGTTCCCACCTTACTACAT, 746-764, Accession No. NM_004559.3) were cloned 
into U6 promoter pshuttle vector (Agilent), respectively. The scrambled 21 mer 
control shRNA sequence is GAAGAGGACACGCCTTAGACT. Adenovirus particles 
were produced in HEK293 packaging cells, and used for infecting the cells using the 
AdEasy Adenoviral Vector System following the manufacture’s protocol (Cell 
Biolabs, Inc, USA). Two YB1 shRNA adenovirus were used concurrently for 
knocking down YB1 expression.  
 
Results 
RECQL4 expression is up regulated in human gastric cancer samples 
To verify whether or not RECQL4 expression is aberrantly elevated in human GC 
cells, RECQL4 mRNA level was first determined by real-time quantitative PCR 
using TissueScan Human gastroesophageal cancer tissue qPCR array (Origene). This 
array contains cDNA samples of 3 normal gastric tissues (*marked), and 20 GC 
samples (*marked) with different pathological grades. Other specimens include 3 
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normal esophageal and 20 esophageal tumor tissues (unmarked). As shown in Figure 
1A, 75% (15/20) of GC tissues displayed a 2.5-fold higher level of RECQL4 mRNA 
than normal tissues. RECQL4 protein level was next examined by Western blotting 
in 11 pairs of human GC samples and matched normal controls. In corroboration 
with elevated RECQL4 mRNA expression in the clinical GC samples, RECQL4 
protein elevation was also observed in 8/11 GC samples (Fig. 1B). 
 
High cytoplasmic RECQL4 expression correlates with poor survival of GC 
patients 
In this study, 92 of 148 tumor cores were found suitable for analysis as some cores 
within the TMA were missing or lacked tumor and these were eliminated from 
analysis. Low levels of nuclear and cytoplasmic RECQL4 expression were found in 
18 of 92 (19.6%) samples, while 29 of 92 (31.5%) samples showed high nuclear and 
low cytoplasmic expression. Further, low nuclear/high cytoplasmic RECQL4 
expression was observed in 22 of 92 (23.9%) samples and high nuclear/high 
cytoplasmic RECQL4 was found in 23 of 92 (25%) samples (Figure 1C). As shown 
in Supplementary Table S2, compared to tumors with low RECQL4 protein 
expression, RECQL4 high nuclear or high nuclear/cytoplasmic co-expression 
correlated well with grade III tumors (p=0.048), tumor vascular invasion (p=0.001) 
and circumferential resection margin (p=0.041), suggesting that RECQL4 high 
expression has a potential role during GC tumor progression. Interestingly, tumors 
with high cytoplasmic RECQL4 expression had poor disease specific survival 
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(p=0.05). While RECQL4 nuclear expression alone did not influence survival 
(p=0.547), tumors with both high nuclear/cytoplasmic RECQL4 appeared to have 
poor survival compared to tumors with low nuclear/cytoplasmic RECQL4 expression 
(p=0.05, Fig.1D). It is to be mentioned that these patients received only surgery but 
not any adjuvant/neoadjuvant chemotherapy.  
 
RECQL4 gene is wild type in both GC cells and clinical GC specimens with high 
RECQL4 expression 
To clarify whether or not the oncogenic property is driven by gain of function 
owing to mutations in RECQL4, the status of RECQL4 gene was analyzed in 7 GC 
cell lines and 11 human surgical GC specimens by PCR-based single-strand 
conformation polymorphism (PCR-SSCP) analysis. The primer sets for 21 exons of 
RECQL4 coding region and sizes of PCR products were summarized in 
Supplementary Table S3. As shown in Supplementary Fig. S1-3, abnormal SSCP 
band migration in comparison with normal control was observed only in exons 2-3 of 
RECQL4 gene in AGS and HGC-27 tumor cells. Further sequencing results 
demonstrated a synonymous GAG to GAA mutation (Glu-Glu at aa 44) in both cell 
types. In support, genetic polymorphism at this locus has been reported previously by 
others (12, 25). These results clearly demonstrated that RECQL4 is wild-type in both 
GC cells and surgical GC specimens. 
 
Elevated RECQL4 expression renders the GC cells more resistant to cisplatin 
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treatment 
We wished to verify whether or not elevated RECQL4 expression confers cisplatin 
resistance in GC cells. For this purpose, we first examined the RECQL4 protein level 
in 7 GC cell lines in relative to normal gastric epithelium. In corroboration with 
elevated RECQL4 mRNA expression in the clinical GC samples, RECQL4 protein 
level was also elevated in all the GC cell lines with a much higher level in 4 of the 7 
cell lines including AGS, NCI-N87, HGC-27 and SNU-16 when compared to normal 
control (Fig. 2A). Then the sensitivity to cisplatin treatment was tested by seeding 
the GC cells at a density of 5,000 cells and treated with graded concentrations of 
cisplatin (0, 0.5, 1, 1.5, 2, 2.5 μg/ml). Cell viability was quantified by the MTT assay. 
As shown in Figure 2B, NCI-N87, AGS and SNU-16 cells with high RECQL4 
expression displayed a significantly higher resistance to cisplatin treatment. In 
contrast, a much lower cisplatin resistance was observed in MGC-803 cells with a 
relatively lower RECQL4 expression. Three cell lines with high (HGC-27) and low 
(MKN45, SNU-1) RECQL4 expression showed an intermediate response to cisplatin. 
Taken together, our results showed a reasonably good correlation between RECQL4 
expression and cisplatin resistance for most of the GC cell lines examined.  
 
RECQL4 physically interacts with YB1 
Correlation observed between RECQL4 expression and cisplatin resistance 
prompted us to examine the downstream signaling pathway(s) that may be regulated 
by RECQL4. Immunoprecipitation coupled with mass spectrometry was performed 
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using the lysates of Flag-RECQL4 transfected HEK293 cells. Among the list of 
candidates identified to interact with RECQL4, YB1 was chosen because YB1 had 
the highest score in mass spectrometry analysis. Furthermore, YB1 was demonstrated 
to be not only a transcription factor but also involved in multidrug resistance through 
regulation of downstream genes such as MDR1 and major vault protein (MVP) genes 
(26, 27). Interaction between RECQL4 and YB1 was then tested in Flag-RECQL4 
overexpressed U2OS cells by co-IP assay. Endogenous YB1 was detected in 
anti-Flag pull-down lysate with anti-YB1 antibody by Western blotting (Fig. 3A). 
Likewise, endogenous RECQL4 was observed in anti-YB1 pull-down complex (Fig. 
3B), illustrating the interaction between RECQL4 and YB1. YB1 has been shown to 
be downstream substrate for AKT (28). In support, AKT was detected in the 
immunoprecipitated complex using either anti-Flag to Flag-RECQL4 or anti-YB1 
antibodies (Fig. 3A & 3B), suggesting that RECQL4 physically interacts with YB1 
and AKT. 
 To further confirm the nature of interaction, purified GST-AKT, His-YB1 and 
His-RECQL4-Flag proteins expressed in E. coli BL21 and detected by Coomassie 
brilliant blue staining (Supplementary Fig. S4) were used for the in vitro pull-down 
assays. Purified His-RECQL4-Flag protein was immobilized on Flag beads and then 
incubated with His-YB1. Purified GST-AKT was immobilized on glutathione 
Sepharose beads, and incubated with His-YB1 and/or His-RECQL4-Flag protein. 
Consistent with the IP results, His-YB1 was pulled down with His-RECQL4-Flag 
(Fig. 3C), and also with GST-AKT not by GST alone (Fig. 3D), suggesting a direct 
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interaction between RECQL4 and YB1 as well as AKT and YB1. His-RECQL4-Flag 
can only be pulled down by GST-AKT in the presence of YB1 (Fig. 3D), suggesting 
an YB1-dependent interaction between RECQL4 and AKT. Through mapping the 
domain of YB1 protein specifically interacting with RECQL4 using various 
GFP-YB1 mutants, the fragment 130-205 aa of YB1 was demonstrated to be 
responsible for the interaction with RECQL4 (Supplementary Fig. S5).  
 
AKT and YB1 association was enhanced in the presence of RECQL4 
Observation of physical interaction between RECQL4 and YB1 prompted us to 
examine whether or not RECQL4 promotes the association of YB1 with AKT. In 
vitro pull-down assay (Fig. 3E) revealed that AKT and YB1 interaction was markedly 
increased by 2.3- to 5.7-fold when RECQL4 protein input was increased from 0 to 
0.2 μg (+) and 1 μg (++), respectively. Additionally, YB1 and AKT interaction was 
detected mainly in the cytoplasmic fraction, and their interaction in the cytoplasmic 
fraction was substantially enhanced when RECQL4 was induced in 
MGC-803/Tet-on/Flag-RECQL4 cells (Supplementary Fig. S6).   
  
RECQL4 promotes AKT-dependent YB1 phosphorylation 
It has been reported previously that YB1, being one of the substrates for AKT, 
enters into nuclear compartment and binds to the promoter region of targeted genes 
when phosphorylated by AKT (29). Our findings of enhanced association of YB1 and 
AKT by RECQL4 led us to investigate whether or not RECQL4 regulates the level of 
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YB1 phosphorylation in GC cells. AGS cells with high RECQL4 expression and 
RECQL4-inducible MGC-803 cells with low RECQL4 expression were used for 
evaluating the role of RECQL4 in AKT mediated YB1 phosphorylation. 
Immunofluorescent staining results showed that p-YB1 in nuclear was substantially 
enhanced in RECQL4-induced MGC-803/Tet-on cells (Fig. 4A), whereas it was 
significantly decreased in RECQL4-suppressed AGS cells (Fig. 4B), suggesting that 
RECQL4 regulates YB1 phosphorylation and its subsequent recruitment into the 
nuclear compartment. Consistently, Western blotting analysis showed an increased 
p-YB1 level in RECQL4-induced MGC-803/Tet-on cells (Fig. 4A). Likewise, 
RECQL4 suppression in AGS cells resulted in a reduction in YB1 phosphorylation 
(Fig. 4B). However, AKT phosphorylation was unaffected either by RECQL4 forced 
expression or suppression indicating that RECQL4 performs its functions just 
downstream of AKT. Inhibition of AKT phosphorylation by treating the above cells 
with 1 μM of MK-2206 (a p-AKT inhibitor) for 2 h specifically abolished YB1 
phosphorylation (Fig. 4A and 4B). This finding together with an elevated YB1-AKT 
interaction by the increased RECQL4 protein input (Fig. 3E) suggests that RECQL4 
promotes AKT-mediated YB1 phosphorylation probably through facilitating the 
recruitment of YB1 to AKT by some unknown mechanism.   
 
RECQL4 status affects the expression of YB1-targeted genes 
We next wished to verify whether or not RECQL4 affects the expression of 
YB1-targeted genes such as MDR1 and MVP (26, 30) through modulating p-YB1 
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level. To this aim, we employed real-time RT-PCR to quantify the mRNA levels of a 
list of drug-resistance related genes, including MDR1, MRP1-MRP4, BCRP and MVP. 
The primer sets for a list of drug resistance-related genes was listed in 
Supplementary Table S4. As shown in Figure 5A, only two of the YB1 targeted genes, 
MDR1 and MVP, were markedly up-regulated upon RECQL4 induction in 
MGC-803/Tet-on/Flag-RECQL4 cells. Elevated MDR1 and MVP proteins upon 
RECQL4 induction was validated by Western blotting (Fig. 5A). We further tested 
MDR1 and MVP protein levels in GC cell lines with varying expression levels of 
RECQL4. Consistently, cell lines with high RECQL4 expression (AGS, HGC-27, 
NCI-N87, SNU-16) had a much higher MDR1 at both mRNA and protein levels 
relative to cell lines with lower RECQL4 expression (MGC-803, MKN45, and 
SNU-1, Fig. 5B). Three GC cell lines (AGS, NCI-N87, SNU-16) with high RECQL4 
expression also have a higher MVP expression at both mRNA and protein levels. 
HGC-27 cells were found to be an exception with low MVP expression despite a high 
endogenous RECQL4 expression (Fig. 5C). Consistent with the potentiation of YB1 
phosphorylation by RECQL4, expression of YB1 target genes was also enhanced as a 
function of RECQL4 expression.  
 
RECQL4 regulates MDR1 expression in a YB1-dependent manner 
First, MDR1 expression was quantified by real-time RT-PCR in 
RECQL4-suppressed AGS cells with or without YB1 suppression. As shown in 
Figure 6A, suppression of either YB1 or RECQL4 led to a decreased MDR1 
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expression, whereas no synergistic effect was observed with simultaneous silencing 
of both YB1 and RECQL4. Luciferase reporter assay was then employed in a 
reconstituted system to determine whether or not regulation of MDR1 expression by 
RECQL4 is dependent on YB1. Native YB1 was first silenced in 
MGC-803/Tet-on/Flag-RECQL4 cells by adenovirus-mediated YB1 shRNA. MDR1 
promoter reporter plasmid was then co-transfected with YB1-expressing plasmid with 
or without RECQL4 induction. Luciferase activities were measured at 72 h post 
transfection. As shown in Fig. 6B, MDR1 promoter activity was at a very low level in 
YB1-silenced cells, however, it was markedly increased by about 5-fold after YB1 
reconstitution. Additionally, only RECQL4 induction in YB1-suppressed cells failed 
to activate the MDR1 promoter. In contrast, reconstitution of both RECQL4 and YB1 
significantly increased the MDR1 promoter activity in relative to YB1 reconstitution 
or RECQL4 induction only (Fig. 6B). p-AKT inhibition by treating the cells with 1 
μM of MK-2206 (a p-AKT inhibitor) for 2 h specifically abolished the YB1 
phosphorylation and subsequent MDR1 activation even in the presence of RECQL4 
induction. These results convincingly demonstrate that MDR1 expression is 
dependent on RECQL4-mediated transactivation potential of YB1. As with MDR1 
promoter, MVP promoter activation was also observed by a luciferase reporter assay 
upon reconstitution of either YB1 alone or YB1 and RECQL4 in YB1-silenced 
MGC-803/Tet-on/Flag-RECQL4 cells (Supplementary Fig. S7), suggesting that both 
of MDR1 and MVP are downstream of RECQL4-YB1 signal pathway.  
We further carried out in vitro electrophoretic mobility shift (EMSA) assay and 
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demonstrated both a direct binding of YB1 protein and a YB1-dependent binding of 
RECQL4 protein to MDR1 promoter (Supplementary Fig. S8). To evaluate the 
binding efficiency of YB1 to MDR1 promoter, a quantitative PCR-based chromatin 
immunoprecipitation (ChIP) assay was performed in 
MGC-803/Tet-on/Flag-RECQL4 cells. As shown in Figure 6C, YB1 binding to 
MDR1 promoter was increased by over 7-fold when RECQL4 was induced, further 
pointing to the critical role of RECQL4 in regulating YB1 and MDR1 activation.  
 
RECQL4 expression level governs cellular sensitivity to cisplatin 
We next determined whether or not cisplatin sensitivity is altered after modulating 
RECQL4 expression in GC cells. As shown in Figure 7A, forced RECQL4 expression 
in GC cells (MKN45, SNU-1 and MGC-803) led to an increased level of MDR1, 
MVP and p-YB1, and consequently, a significantly higher cellular viability after 
cisplatin treatment when compared with their controls. Conversely, both a suppressed 
level of MDR1, MVP and p-YB1, and a significantly decreased cellular viability 
were observed after RECQL4 suppression in NCI-N87 and AGS cells when exposed 
to different concentrations of cisplatin (Fig. 7B). RECQL4 Suppression in HGC-27 
cells led to reduced p-YB1 and MDR1 levels as expected but MVP level was not 
altered, suggesting that RECQL4-YB1-MDR1 axis is critical for cisplatin sensitivity. 
The findings also imply that the role of MVP in drug sensitivity is not essential yet 
all the responding cells with exception of HGC-27 show a positive correlation 
between MVP expression level and drug sensitivity modulated by RECQL4. 
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Discussion 
The most commonly used treatment regimen in gastric cancer is cisplatin-based 
chemotherapy (28), however, many gastric cancer patients have cancer recurrence 
after initial therapy and become refractory to chemotherapy following treatment. 
Thus, acquisition of cisplatin resistance is a major clinical obstacle for successful 
treatment of gastric cancer. However, the molecular basis for cisplatin resistance in 
GC is not clearly understood. In this study, we have presented a number of novel 
features that suggest prognostic and therapeutic significance of RECQL4 in GC: (I) 
increased expression in GC cell lines and primary clinical samples; (II) correlation 
between high cytoplasmic or nuclear/cytoplasmic expression of RECQL4 with poor 
survival of GC patients; (III) correlation between high RECQL4 expression with 
cisplatin resistance; (IV) identification of physical and functional interaction of 
RECQL4 with a major transcription factor YB1; (V) promotion of RECQL4 
mediated YB1 phosphorylation by AKT and (VI) transcriptional activation of a 
multidrug resistance gene MDR1 by YB1 is regulated by RECQL4 expression. 
We have utilized 7 different GC cells lines in this study, whose genetic makeup is 
expected to be different from one another. Further, mutational spectrum of genes as 
well as the number of genes mutated may also considerably vary. These intrinsic 
features may influence their cellular phenotypes in vitro especially when these cells 
are challenged by exogenous DNA damage causing agents like cisplatin. In spite of 
the intrinsic variations, a reasonably good correlation between RECQL4 expression 
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and cisplatin sensitivity was observed in most of the GC cell lines used in this study. 
Although cisplatin resistance was only marginally increased by forced RECQL4 
expression in some of the GC cell lines with low endogenous RECQL4 expression, 
the acquired resistance was found to be statistically significant. It is likely that other 
unidentified mechanism(s) independent of RECQL4 may also contribute to chemo 
resistance phenotype in GC cells.  
 Demonstration of a physical interaction, for the first time in this study between 
RECQL4 and YB1 indicates the functional significance of RECQL4 upregulation in 
carcinogenic process (31, 32). YB1 is an oncogenic transcription/translation factor 
that is overexpressed in a number of cancer types, and is frequently associated with 
poor outcome and chemotherapy resistance (27, 33). Being a substrate of AKT, YB1 
can be phosphorylated at serine 102 by AKT, which is required for YB1 nuclear 
translocation in cancer cells (28, 34). In support, we found that RECQL4 
substantially enhances the interaction between AKT and YB1 resulting in an 
increased level of p-YB1, illustrating a functional link between RECQL4 
overexpression and YB1 activation. Moreover, our data suggest that RECQL4 
functions just downstream of AKT and modulates AKT-dependent YB1 
phosphorylation possibly by forming a functional complex with AKT through YB1.       
Overexpression of the MDR1 gene and corresponding P-glycoprotein (Pgp) efflux 
pumps is one of the best characterized MDR mechanisms, leading to resistance to a 
wide variety of anticancer agents in many types of human cancers (35-37). MDR1 
expression was shown to be regulated by transcription factors such as YB1 (35). 
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Previous studies have illustrated a plausible association between YB1 and drug 
resistance in both cultured cancer cells and clinical tumor samples (38, 39). However, 
there are certain gaps in our understanding with regard to how YB1 becomes 
activated to induce the expression of MDR1 in cancer cells. Here, we provided 
evidence that induced expression of RECQL4 in MGC-803/Tet-on/Flag-RECQL4 
cells led to a markedly increased level of MDR1 expression. In particular, a fair 
correlation between RECQL4 status and MDR1 level was observed in GC cell lines 
tested. Moreover, ectopic expression of RECQL4 in GC cells was observed to 
enhance the YB1 phosphorylation and further its nuclear translocation, and vice 
versa. The results of Luciferase reporter and ChIP-qPCR assays showed that 
RECQL4 has the potential to modulate MDR1 promoter activity by a YB1-dependent 
manner. This finding attributes an essential role to RECQL4 in regulating the chemo 
resistance of GC cells through regulation of YB1-AKT-MDR1 downstream pathway.   
Based on our findings, we suggest that RECQL4 is a novel therapeutic target for 
GC and efficient RECQL4 mediated targeting of AKT-YB1-MDR1 pathway is an 
effective treatment strategy for chemo sensitization of GC. Since RECQL4 has 
demonstrated roles in DNA replication and repair (40, 41), RECQL4 targeting may 
have additional advantages for cancer therapy. 
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Figure Legends:  
Figure 1. RECQL4 expression in clinical gastric cancer (GC) specimens. (A) 
RECQL4 mRNA level determined by quantitative real time PCR in normal gastric 
tissues and GC specimens with different pathological grades (TissueScan cDNA 
array, Origene). Normal gastric and cancer specimens were marked with asterisks (*). 
Other unmarked samples were esophageal tissue specimens. The values represent 
mean ± SD from three independent experiments. (B) RECQL4 protein level in 11 
pairs of human GC (T) and matched normal gastric controls (N) determined by 
Western blotting using RECQL4 antibody from Novus Biologicals. (C) 
Microphotographs of RECQL4 protein expression in gastric adenocarcinomas. 
RECQL4 antibody from Novus Biologicals was used for IHC staining. (D) Kaplan 
Meier curves showing disease specific survival based on RECQL4 protein 
expression in different cellular compartments.  
 
Figure 2. RECQL4 expression level affects sensitivity to cisplatin treatment. 
(A)RECQL4 protein level in GC cell lines determined by Western blotting using 
RECQL4 antibody from Novus Biologicals. (B) Viability of GC cells after treatment 
with graded concentrations of cisplatin for 72 h was quantified by MTT assay with 
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10 duplicated wells for each time-point of each cell line. The values represent mean 
± SD from three independent experiments.  
 
Figure 3. RECQL4 physically interacts with YB1. (A) Endogenous YB1 and AKT 
were detected in anti-Flag immunoprecipitates against Flag-RECQL4. Flag-GFP 
immunoprecipitates were used as negative controls. (B) Endogenous RECQL4 and 
AKT were detected in anti-YB1 (Cell Signaling) immunoprecipitates determined by 
Western blotting analysis. (C) Direct interaction between RECQL4 and YB1, and (D) 
indirect interaction between RECQL4 and AKT were demonstrated by in vitro 
pull-down assay. (E) An enhanced interaction between AKT and YB1 was observed 
upon an increased input of RECQL4 protein (antibody from Cell signaling). The 
pull-down YB1 protein was quantified using the Image J software 
(http://rsbweb.nih.gov/ij/) and normalized to AKT loading control.   
 
Figure 4. RECQL4 potentiates YB1 phosphorylation in an AKT-dependent manner. 
Level of p-YB1 determined by immunofluorescent staining and Western blotting 
analysis in: (A) MGC-803/Tet-on/Flag-RECQL4 cells upon RECQL4 induction and 
(B) AGS cells upon adenovirus-mediated RECQL4 silencing with or without 
treatment of AKT inhibitor-MK-2206. RECQL4 antibody from Novus Biologicals 
was used. Images were captured by Leica TCS SP5 Confocal microscope. 
Fluorescent staining of p-YB1 in nucleus was quantified by Image J software 
(http://imagej.net/Welcome). At least 200 cells were analyzed for each sample. 
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Values represent the mean ± SD.  
  
Figure 5. RECQL4 modulates MDR1 expression. (A) The relative mRNA levels of a 
list of drug resistance-related genes were quantified by real time RT-PCR in 
MGC-803/Tet/on/Flag-RECQL4 cells after RECQL4 induction. Levels of MDR1, 
MVP, p-YB1 and p-AKT proteins were examined by Western blotting. (B) 
Expression of MDR1 (B) and MVP (C) at both mRNA and protein levels in GC cell 
lines determined by quantitative real time RT-PCR and Western blotting analyses. 
RECQL4 antibody was from Novus Biologicals; MDR1 (Cat. ab129450) and MVP 
(Cat. ab175239) antibodies were from Abcam. 
 
Figure 6. RECQL4 regulates MDR1 in a YB1-dependent manner. (A) MDR1 
expression was quantified by real time RT-PCR in AGS cells after YB1 and/ 
RECQL4 suppression. RECQL4 antibody from Cell Signaling was used. (B) Effect 
of YB1 and RECQL4 on MDR1 promoter activity determined by a reconstitution 
assay in MGC-803/Tet-on/Flag-RECQL4 cells. Protein levels of RECQL4 (antibody 
from Novus Biologicals), p-YB1 and p-AKT as well as relative luciferase activity 
were then determined. (C) YB1 binding ability to MDR1 promoter region was 
quantified by a PCR-based ChIP assay. Values represent the mean ± SD from three 
independent experiments. 
 
Figure 7. Altered sensitivity to cisplatin by modulating RECQL4 expression. 
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RECQL4 expression was reconstituted in MKN45, SNU-1, MGC-803 cells (A) or 
suppressed in NCI-N87, AGS, HGC-27 cells (B). Levels of RECQL4, MDR1, MVP 
and p-AKT proteins were determined by Western blotting. RECQL4 antibody from 
Novus Biologicals was used. Cellular viability after treatment with graded 
concentrations of cisplatin was quantified by MTT assay. The data in the curves 
represent mean ± SD from three independent experiments. Student’ t-test was used 
for statistical analysis. 
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Supplementary Table S1: Clinicopathological characteristics  
of patients with early gastric adenocarcinomas (n=148) 
 
Age (Median years) 74 (41-90) 
Gender (M/F%) 74 / 26 % 
Tumour site 
Gastric – 87% 
GOJ – 12% 
Oesophageal – 1% 
Grade (1-3) 
 
1 – 9% 
2 – 35% 
3 – 56% 
Tumour depth (T0-4) 
T1 – 10% 
T2 – 33% 
T3 – 54% 
T4 – 3% 
Nodal stage 
N0 – 22% 
N1 – 52% 
N2 – 18% 
N3 – 8% 
Vascular invasion (Y) 67% 
Perineural invasion (Y) 45% 
Status Alive – 37% Dead – 63% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table S2: Correlation of RecQL4 Nuclear & Cytoplasmic expression 
with clinical parameters of gastric cancer patients 
   
 
                    
VARIABLE 
 
RECQL4 Nuclear (Rn) & RECQL4 
Cytoplasmic (Rc) Protein Co-expression 
 
 
 
P-value 
 
Rn-/Rc- 
N (%) 
Rn+/Rc- 
N (%) 
 
Rn-/Rc+ 
N (%) 
 
Rn+/Rc+ 
N(%) 
T Stage 
 T1 
 T2 
 T3 
 T4 
 
3 (16.7) 
6 (33.3) 
8 (44.4) 
1 (5.6) 
 
1 (3.5) 
9 (31.0) 
19 (65.5) 
0 (0.0) 
 
3 (13.6) 
6 (27.3) 
13 (59.1) 
0 (0.0) 
 
1 (4.3) 
6 (26.1) 
14 (60.9) 
2 (8.7) 
 
 
0.485 
Overall Stage 
 Stage 1 
 Stage 2 
 Stage 3 
 Stage 4 
 
2 (11.1) 
7 (38.9) 
9 (50.0) 
0 (0.0) 
 
1 (3.4) 
11 (37.9) 
17 (58.7) 
0 (0.0) 
 
3 (13.6) 
6 (27.3) 
13 (59.1) 
0 (0.0) 
 
1 (4.3) 
6 (21.7) 
15 (65.3) 
2 (8.7) 
 
 
0.332 
LN status            
Negative 
Positive 
 
 
6 (33.3) 
12 (66.7) 
 
 
6 (20.7) 
23 (79.3) 
 
 
6 (27.3) 
16 (72.7) 
 
 
2 (8.7) 
21 (91.3) 
 
 
0.247 
Tumour Grade        
 G1/G2 
 G3 
   
 
10 (55.6) 
8 (44.4) 
 
 
6 (20.7) 
23 (79.3) 
 
 
8 (36.4) 
14 (63.6) 
 
12 (52.2) 
11 (47.8) 
 
 
0.048 
CRM Involvement 
No 
Yes 
 
 
3 (75.0) 
1 (25.0) 
 
  
0 (0.0) 
4 (100.0) 
 
 
0 (0.0) 
5 (100.0) 
 
 
2 (33.3) 
4 (66.7) 
 
0.041 
Vascular Invasion     
No 
Yes 
 
 
7 (38.9) 
11 (61.1) 
 
 
6 (20.7) 
23 (79.3) 
 
 
12 (54.5) 
10 (45.5) 
 
 
1 (4.3) 
22 (95.7) 
 
 
0.001 
Perineural Invasion    
No 
Yes 
 
 
11 (61.1) 
7 (38.9) 
 
 
13 (44.8) 
16 (55.2) 
 
 
15 (68.2) 
7 (31.8) 
 
 
12 (52.2) 
11 (47.8) 
 
 
0.376 
CRM: Circumferential resection margin 
Supplementary Table S3. Primer sets of 21 exons of human RecQL4 gene for 
PCR-SSCP analysis (Exon 5 was divided into three fragments: E5.1-E5.3) 
 
SSCP Primers Design 
primer name primer sequence(F) primer sequence(R) Product 
size(bp) 
E1 GGAGATTCGCTGGACGAT CTGTAAAGGGAACGCGTCAG 200 
E2-E3 CTGACGCGTTCCCTTTACA AAACAGGGAAGTGGGAGGAG 286 
E4 ACAGCCTTTTCTGGCCTGT GAAGCAGCTGTGGACCTAGC 228 
E5.1 CCTGAGTTCCTCCTGCTGTT CGACTCACCAGGGATCAGAA 359 
E5.2 GCCTGATCTAGGCTCAGAGG TGGAGGGTCTTCCTCAACTG 271 
E5.3 CAGTTGAGGAAGACCCTCCA AAAGGGAATGCCTGTCCTG 290 
E6 CCCAGTGACCCTCCTATGTG CTCCAGGGCAGATGTCTCAC 179 
E7 GCTCCCATTCTACCCTCTCC TGACTTGAGTCACCCCAACC 222 
E8 GGGTGACTCAAGTCATGGTGA GTGGAGATGCCTGGATGG 220 
E9 CAGAACCCTGCTGCTGACTC AAGTGCTGGTTCTTGGCTGT 220 
E10 GCTGTCGCTCCTGCATTT CTGCCTCCCTCACCCCTA 142 
E11 CCTCTGATCTTGCTGCCTTC CCCAGTTCACATATGGCTCA 217 
E12 GCAAGGTGAGCCATATGTGA GGTCCCCAGAGCACACAC 290 
E13 GCCAACCGCTCCTCATC ACACCAGCTCTGTCCATGC 185 
E14 CACTGACCATCTGCCTGTCT GGTGGGGTGGACCACTG 350 
E15 CACCCCACCCTCATGAAA GCTTACCCCAGGTTCCTCAC 342 
E16 GGGTAAGCCACAGGGGTGT   CTCCAACCTCGTCTCCAACT 230 
E17 GGCCACATGTCCCTTTTTC    GGAAAGCATGTCAGATGCAG  262 
E18 CTGCATCTGACATGCTTTCC   CTACGCTGTGGGGAGGAG    287 
E19 ACAGGCTCCTCCCCACAG    CCTGGCCTTACTGCACTCAC    195 
E20 GAAGCCTGATGTGCCTGTC   CAAGACACAGCCGTGAGC  248 
E21 GTGTCTTGGCTCCACCGTAG   CTGCCCTAGCCTCTGACAAC   200 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table S4. PCR primer sets of drug-resistance related genes used for 
real-time RT-PCR analysis 
Gene name  Sequence Length (bp) 
MRP1 F AAGGGATCGCCGTGTTTGG 428  R CGAAGGCTCGAATGACGCTGAC 
MRP2 F CCTGGTTCCTGTCCCTATTCT 472  R GGCATCTTGGCTTTGACTCTG 
MRP3 F CGCCACAGTCCTTCTTTGACACCAC 443  R CCACGAACTCCACTCCGATGCTC 
MRP4 F TTGGGATAAGGCATCAGAGACC 463  R AGTGTCTGCTAACTTCCGCATCTAC 
BCRP F GGCCTATAATAACCCTGCAGACTTC 391  R GCCCAAAGTAAATGGCACCT 
MVP F TTTGATGTCACAGGGCAAGTTCGGC 425  R CACCAAATCCAGAACCTCCTCAAAC 
MDR1 F GAGCCCATCCTGTTTGACTGC 411  R TGCCATGCTCCTTGACTCTGC 
β-actin F AGCGAGCATCCCCCAAAGTT 284  R GGGCACGAAGGCTCATCATT 
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Construction of Tissue Microarray (TMA): TMAs were constructed. In short, 
area-specialized histopathologists identified and marked formalin-fixed 
paraffin-embedded tissue blocks containing tumor tissue on haematoxylin and eosin 
stained slides. The marked areas in these donor paraffin blocks were used to construct 
the tissue microarray. Triplicate tissue cores with a diameter of 0.6 mm were taken 
from the marked areas and arrayed into a recipient paraffin block using a tissue 
puncher/arrayer (Beecher Instruments, Silver Spring, MD, USA). Five micron 
sections of the tissue array block were cut and placed on microscope slides (Fisher 
scientific, Pittsburgh, PA) for immunohistochemical staining.  
 
Chemicals  
Cisplatin and p-Akt inhibitor MK-2206 were purchased from Sigma (St. Louis, MO, 
USA) and Selleck (#cat s1078), respectively, and dissolved in DMSO and stored at 
-20°C. Lipofectamine and Trizol reagent were from Invitrogen. Wizard Genomic 
DNA Purification Kit and moloney murine leukemia virus (MMLV) reverse 
transcriptase were from Promega (USA).  
 
Real-time RT-PCR 
The mRNA level for RecQL4 and a list of drug resistance-related genes was 
quantified by Real-time RT-PCR. The primer sets for drug resistance-related genes 
were listed in Supplementary Table S4. All reactions were done in triplicate and three 
independent experiments were performed. RT-PCR amplification results were 
calculated by CFX Manager. The real time PCR primers for RecQL4 are: P1: 
5’-TCACAGTGAGGTCCCAGATT-3’ and P2: 5’-CTGACTTCTTGGAAGGCTG 
A-3’. β-actin was used as the internal control for normalization of RecQL4 mRNA.  
 
Dual-Luciferase assay for MVP 
MVP gene promoter region (from-679 to +23) containing Y-box consensus 
sequence used for luciferase reporter assay was ampliﬁed by PCR using the following 
primer pair: forward: 5’-ggggtaccCGTACCTGCTGGAGCCTGG-3’, reverse: 
5’-cccaagcttCCAGGCTCCAGCAGGTACG-3’. The PCR fragment was then cloned 
into the KpnI/HindIII sites of pGL3-Basic vector, and verified by sequencing. The 
pGL3-MDR1pro plasmid was transiently transfected into YB1-silenced 
MGC803/Tet-on/Flag-RecQL4 cells with YB1 reconstitution or/and Dox-induced 
expression of RecQL4. Luciferase activity was measured following the 
dual-luciferase assay protocol (Promega).  
 
In vitro pull-down assay 
For RecQL4 pull-down YB1 assay, purified His-RecQL4-Flag fusion protein were 
bound to Flag M2 beads in buffer A (50 mM Na2HPO4, 150 mM NaCl, 10 mM EDTA, 
0.2-0.5% NP-40, 2 mM DTT, pH7.5) and then incubated with His-YB1 fusion protein 
at 4°C for 2 h. The resins were washed, and the bound protein was detected by 
Western blotting.  
Interactions among RecQL4, YB1 and Akt were then tested by pull-down assay. In 
brief, the bait protein was expressed as a (GST-Akt) fusion protein in E. coli, purifed 
and immobilized on Glutathione resin. Purified His-RecQL4-Flag or/and His-YB1 
was added to the immobilized GST-Akt in buffer A. After gentle rotation at 4°C for 2 
h, the bound proteins were examined by Western blotting.  
To test whether or not RecQL4 promotes the association between Akt and YB1, a 
pull-down assay was further performed by immobilizing 3 μg of GST-Akt on 
Glutathione resin, followed by addition of 1 μg of His-YB1 combined with different 
amounts of His-RecQL4-Flag protein including 0, 0.2 μg (+) and 1 μg (++), 
respectively. Level of YB1 in the bound protein was then quantified by the band 
intensity detected by Western blotting. 
 
Co-immunoprecipitation 
293T cells transfected with Flag-RecQL4 or Flag-GFP were collected in lysis buffer 
(50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP-40, 5 mM EDTA, 5 mM EGTA, 20 
mM NaF, 0.1 mM PMSF, 0.5 mM benzamidine, 1 mg/ml leupeptin, 1 mg/ml aprotinin, 
2 mM microcystin and 0.1 mM NaVO3), and then incubated with anti-Flag-M2 beads 
(Sigma) at 4°C for 2 h. U2OS cells were harvested in lysis buffer and then incubated 
with Dynabeads Protein A that are coated with IgG or anti-YB1 antibody. After 
washing with lysis buffer, the binding complex was heated at 80°C for 10 min in 
1×Laemmli buffer. The RecQL4 complex was visualized by Western Blotting. 
 
Protein expression and purification 
His-YB1 fusion proteins were constructed by cloning full-length human YB-1 into a 
pET-28a vector (Novagen). GST-Akt fusion proteins were constructed by cloning 
full-length human Akt into a pGEX-6p-1 vector (GE Healthcare). The plasmids were 
expressed in BL21 Escherichia coli and induced to express the fusion proteins with 
0.5 mM isopropyl-b-D-thiogalactoside for 3 h at 37°C. The fusion proteins were 
purified by following His or GST tag purification method. Flag-RecQL4 fusion 
protein was constructed by cloning full-length human RecQL4 into pET-16b vector 
(Novagen). Fusion proteins were expressed in Rosetta (DE3) pLysS cells. Cells were 
grown at 37°C to a cell density OD600 0.4～0.5, followed by overnight induction at 
16°C with 0.1 mM isopropyl-β-d-thio-galactoside. Cells were harvested and lysed in 
lysis buffer, followed by sonication. The supernatant was applied to Ni-NTA column, 
washed and eluted. The eluate was dialyzed and incubated with anti-FLAG M2 beads 
(Sigma). The M2-bound proteins were washed, eluted and dialyzed. 
 
Chromatin immunoprecipitation analysis  
Chromatin immunoprecipitation (ChIP) assays were carried out as previously 
described (Zhang Y., et al, Cancer Res., 2009). 1×107 MGC-803 cells were fixed with 
1% molecular grade formaldehyde (Sigma) and sonicated with Bioruptor® Plus 
device. YB1 antibody was used for immunoprecipitation and detected with 
quantitative PCR (BioRad CFX-96 Real-Time PCR System). Data were analyzed by 
delta Ct method. Primers for human MDR1 gene were 5- 
ACCTGTTTCGCAGTTTCTCG -3 (forward) and 5- GAAGAGCCGCTACTCG 
AATG -3 (reverse). Primers used for negative control were 
5-AGGTGGAGAAACACCACCAC-3 (forward) and 5-CGGTTTGCCCAAG 
AAAAATA-3 (reverse). 
 
Electrophoretic mobility shift assays (EMSAs) 
The 5’ Digoxin-labeled oligonucleotide contained the WT 
(5’-GGTGAGGCTGATTGGCTGGGCAGGA-3’) or mutated Y box 
(5’-GGTGAGGCTGATCAACTGGGCAGGA-3’) (underlined WT and mutated 
Y-box sequences were annealed with appropriate complementary stands to generate 
the duplex oligonucleotides)( Chattopadhyay R., Mol. Cell Biol., 2008). Each 
oligonucleotide (20 ng) was then incubated with 100 ng of YB-1 or YB-1 smaller 
segment (130 to 205 aa) and RecQl4 (100 ng) for 20 min at 25°C in a buffer 
containing 40 mM HEPES-KOH (pH 7.5), 50 mM KCl, 1 mM MgCl2, 0.5 mM 
EDTA, 0.5 mM dithiothreitol, 10% glycerol, and 1 μg of poly(dI-dC) (Sigma). After 
electrophoresis in nondenaturing 6% polyacrylamide gels in Tris-borate buffer at 4°C, 
the gels were transferred and crosslinked for 120 mJ/cm2 by Bio-Link Crosslinker 
BLX-E254. Binding reactions were performed using a LightShift Chemoluminescent 
EMSA Kit according to the manufacturer's instructions (Thermofisher). 
 
PCR-SSCP protocol 
2 µl PCR product and 10 µl loading buffer (10% sucrose with a little bromophenol 
blue) is denatured at 95°C for 10 minutes and immediately kept on ice for 5 minutes, 
then the samples are loaded on a nondenaturing 8% acrylamide: bis-acrylamide (49:l) 
gel and immediately electrophoresis is performed in 1 X TBE buffer at 200 V for 1hr 
at 4℃. After the electrophoresis, the gel is fixed in 10% methanol and 0.5% acetic 
acid for 10min on a shaker, then put the gel into 0.1% silver nitrate solution staining 
for 10min in dark on a shaker. The gel is rinsed briefly for 10 seconds in distilled 
water and the freshly prepared and chilled 1.5% sodium hydroxide solution (1.5% 
NaoH + 0.15% formaldehyde) is transferred to the tray. The gel is kept immersed until 
bands get developed sharply. Then gel is labeled and scanned for computer image 
analysis and documentation.  
 
 
